Back to Directory
biotechnology logo

Nurix Therapeutics | Company Profile

10/21/2025

Contact Information

👤
Nurix Therapeutics
🏢
Nurix Therapeutics
📍
1700 Owens Street, Suite 205, San Francisco, CA 94158, US

Industry & Market

Primary Industry
biotechnology
All Industries
biotechnologyresearch
Location
San Francisco, California, United States
Public Trading
NASDAQ: NRIX

Company Metrics

👥Total Employees
76
⚙️Engineering
5
💼Sales Team
N/A
📈Marketing
1
📅Founded
2012
💰Revenue
88.4M

Funding Information

Market Cap
$830.2M
Annual Revenue
$88,381,000
Publicly traded company

Headcount Distribution

Total Employees
76
Departments
19

By Department

Department Breakdown

Operations
Information Technology
Consulting
Human Resources
Engineering
Finance
Others

Technology Stack

Video & Media

Vimeo

Email & Communication

Outlook
Total: 26 technologies

Keywords & Focus Areas

researchlife sciencesbiotechnologybiotechnology: pharmaceutical preparationshealth careautoimmune diseasesdna-encoded library technologybiotech collaborations with pharmacancer immunotherapytargeted protein degradation platforme3 ligase biochemistryclinical developmentprotein targetingresearch and development in the physical, engineering, and life sciencesdna-encoded librariesdrug discovery platformbiological researchubiquitin-proteasome systembiotech collaborations in pharmaautoimmune disease therapies+10 more
30 total keywords

Nurix Therapeutics

Overview

Nurix Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, founded in 2009. The company focuses on discovering, developing, and commercializing small molecule therapies that target E3 ubiquitin ligases, which play a crucial role in the protein degradation process within cells. Nurix utilizes its proprietary DEL-AI discovery engine, combining DNA Encoded Libraries, automated chemistry, and machine learning to create innovative degrader-based medicines.

The company primarily targets immune-mediated diseases, hematologic cancers, and immuno-oncology. Its clinical pipeline includes drug candidates like NX-2127 and DeTIL-0255, which are currently in trials for various cancers and autoimmune conditions. The organization has formed strategic collaborations with major pharmaceutical companies such as Gilead Sciences, Sanofi, Pfizer, and Bristol Myers Squibb, enhancing its capabilities in drug discovery and development. It is publicly traded on NASDAQ under the ticker NRIX.

Basic Information

Industrybiotechnology
Founded2009
Revenue88.4M
Headquarters1700 Owens Street, Suite 205, San Francisco, CA 94158, United States
LanguagesEnglish
Alexa RankingN/A

Contact Details

Key Focus Areas & Initiatives

  • Small molecule therapies targeting E3 ubiquitin ligases
  • DNA-encoded library technology (DEL-AI discovery engine)
  • Immune-mediated diseases
  • Hematologic cancers
  • Immuno-oncology
  • Degrader-based medicines
  • Clinical pipeline development
  • Strategic pharmaceutical collaborations
  • Drug discovery and development
  • Protein degradation technology
  • Machine learning in drug discovery

Technologies Used

  • AI
  • Amazon AWS
  • Amazon SES
  • Android
  • Atlassian Cloud
  • CloudFlare Hosting
  • Cloudflare DNS
  • Google Cloud Hosting
  • Google Font API
  • Google Maps
  • Google Maps (Non Paid Users)
  • Greenhouse.io
  • Micro
  • Microsoft Office 365
  • Mimecast
  • Mobile Friendly
  • New Relic
  • Nginx
  • Outlook
  • Remote
  • Salesforce
  • Typekit
  • Vimeo
  • WP Engine
  • WordPress.org
  • reCAPTCHA

Affiliated Organizations & Regional Branches

Need more information?

Find decision makers, more insights and contact information about this company on Bitscale

Try Bitscale Now

Schedule your demo now!

See how BitScale can supercharge your outbound sales in a 30-minute demo

SayData

© 2025 Bitscale. Featherflow Technology Pvt Ltd

LinkedInTwitterInstagramYouTube